- DKK101.26bn
- DKK126.40bn
- $3.72bn
Earnings Poll: Genmab A/S third quarter results due on November 6
Brief: Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan Achieved Anti-Tumor Activity In Heavily Pretreated Patients
Brief: Genmab: Darzalex Q3 Net Sales Total $3,672 Mln
TD Cowen raises Genmab's TP, calls $8 bln acquisition 'good strategic' deal
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Brief: Merus NV To Pay Genmab $240 Million Termination Fee Under Certain Conditions If Deal Falls Through - SEC Filing
Merus jumps on Genmab's $8 billion buyout deal
Live Markets: FTSE edges toward record as healthcare stocks surge
Genmab falls as it agrees to acquire Merus
Live Markets: Before the bell: futures up, Lufthansa cuts jobs, GSK CEO steps down
Press Digest: Wall Street Journal - September 29
Brief: Genmab To Buy Merus For USD 8.0 Billion
Genmab to buy Dutch cancer drugmaker Merus for $8 billion (updated)
Genmab nears deal to acquire Dutch cancer drugmaker Merus, Bloomberg News reports
Brief: Genmab Is Said To Near Deal To Buy Cancer Drugmaker Merus - Bloomberg News
European pharma stocks largely steady amid new US tariff onslaught
Europe Research Roundup: Ashtead Group, Diploma ,ISS
Brief: Genmab Announces Updated Results From Phase 2 Epcore Nhl-6 Study